Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Vaccine composition, kit and application thereof

A vaccine composition and kit technology, applied in the directions of antiviral agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., can solve problems such as harm and loss, and achieve excellent immune effect, long immune period, good prevention and control. Control the effect of the effect

Active Publication Date: 2021-06-11
PU LIKE BIO ENG
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The CPV strains involved in the current commercial canine parvovirus vaccines are all CPV-2 types that appeared early, and the current popular CPV strains are quite different from them in terms of amino acid levels. The single or mixed infection of canine parvovirus has not been significantly suppressed or reduced in the clinical cases, and it still causes great harm and serious losses to pet dogs, dog breeding and fur economic animal breeding industries.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine composition, kit and application thereof
  • Vaccine composition, kit and application thereof
  • Vaccine composition, kit and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment approach

[0040] As an embodiment of the present invention, the canine parvovirus S0425 strain antigen in the vaccine composition is an inactivated whole virus antigen, and the content of the inactivated whole virus antigen is 10 5 -10 9 TCID 50 / ml.

[0041] As a preferred embodiment of the present invention, the canine parvovirus S0425 strain antigen is an inactivated whole virus antigen, and the content of the inactivated whole virus antigen is 10% before inactivation. 6 -10 8 TCID 50 / ml.

[0042] As a preferred embodiment of the present invention, the canine parvovirus S0425 strain antigen is an inactivated whole virus antigen, and the content of the inactivated whole virus antigen is 10% before inactivation. 7 TCID 50 / ml.

[0043] As an embodiment of the present invention, the other antigens include canine distemper virus antigen, canine adenovirus type I antigen, canine adenovirus type II antigen, canine leptospira antigen, canine coronavirus antigen, canine parainfluenza...

Embodiment 1

[0090] Example 1 Isolation, identification and assay of canine parvovirus

[0091] 1.1 Isolation and identification of canine parvovirus

[0092] The wild strain of CPV was isolated from clinically infected animals with canine parvovirus. The clinical symptoms of infected animals were: anorexia, depression, elevated body temperature, vomiting, loose stools, sticky stools and even tomato sauce-like bloody stools, and dehydration in the later stage of the disease Symptoms, etc., were used as the criteria for selecting animals.

[0093] Dilute the intestinal content of sick dogs to 10% V / V suspension with serum-free RPMI-1640 culture medium, filter and sterilize with a 0.22 μm filter membrane, and inoculate the filtrate with F81 monolayer cells (purchased The virus was isolated from Shanghai Enzyme Detection Technology Co., Ltd., and the cytopathy of the drawing appeared in 24 to 48 hours, and the cytopathy reached more than 80% in about 96 hours. The virus was collected by free...

Embodiment 2

[0099] The preparation of embodiment 2 vaccine composition

[0100] 2.1 Preparation of CPV inactivated whole virus antigen

[0101] The CPV S0425 strain of embodiment 1 is inactivated through the final concentration of 0.025% V / V BPL (beta-propiolactone), and according to "Chinese Veterinary Pharmacopoeia" (Chinese Veterinary Drug Committee, 2010 edition three, China Agricultural Press , 2010) method to carry out sterility test, mycoplasma test and exogenous virus test to CPV, the results show that: after the CPV S0425 strain was inactivated, it was not polluted by bacteria and mold, nor was it infected by mycoplasma and exogenous virus. good.

[0102] 2.2 Preparation of vaccine composition

[0103] The CPV S0425 strain antigen prepared in Example 2.1, other antigens in the prior art, and PET GEL A adjuvant (purchased from SEPPIC, France, with a final concentration of 5%) were prepared according to the components and contents shown in Table 1 with physiological saline soluti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a vaccine composition containing an immune amount of canine parvovirus antigen and an immune amount of other antigens, and also relates to a kit containing an effective amount of canine parvovirus antigen and an effective amount of other antigens, and the prepared vaccine composition Both the method and the kit can be effectively used for preparing medicines for preventing and / or treating diseases related to canine parvovirus infection. The vaccine composition and kit of the invention can effectively prevent the existing wild strains of the circulating canine parvovirus, and have a synergistic effect with some antigens in other antigens to further improve the immune effect of the combined vaccine.

Description

technical field [0001] The invention belongs to the field of veterinary biological products, and in particular relates to a vaccine composition containing canine parvovirus antigen and other antigens, a kit, a preparation method and application thereof. Background technique [0002] Canine parvovirus (Canine Parvovirus, CPV) causes acute onset, short course of disease, high mortality, and strong infectivity. It can infect dogs, foxes, minks, raccoons, and wolves of various ages, sexes, and breeds. Infecting young animals, the mortality rate of animals within 8 weeks of age is as high as 70%, and the mortality rate of animals within 1 year of age can also reach 30%. [0003] Canine distemper virus (CDV) is a viral disease with high morbidity and mortality worldwide. With the change of ecological environment and the evolution of animals and viruses, its host has been changed from the traditional canine Family (including dogs, foxes, raccoon dogs, etc.), Procyonidae and Mustel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/295A61K39/23A61K39/39A61K45/06A61P31/14A61K39/175A61K39/235
Inventor 田克恭吴洪超孙进忠张许科
Owner PU LIKE BIO ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com